Article Versions Notes

Shao S, Li S, Huo Y, Tang S, Gökbağ B, Fan K, Huang Y, Wang L, Nagy G, Parvin J, et al. CRISPR-Cas9 Genome and Double-Knockout Screening to Identify Novel Therapeutic Targets for Chemoresistance in Triple-Negative Breast Cancer. Cancers. 2025; 17(23):3876. https://doi.org/10.3390/cancers17233876

Shao, Shuai, Shangjia Li, Yang Huo, Shan Tang, Birkan Gökbağ, Kunjie Fan, Yirui Huang, Lingling Wang, Gregory Nagy, Jeffrey Parvin, and et al. 2025. "CRISPR-Cas9 Genome and Double-Knockout Screening to Identify Novel Therapeutic Targets for Chemoresistance in Triple-Negative Breast Cancer" Cancers 17, no. 23: 3876. https://doi.org/10.3390/cancers17233876

Shao, S., Li, S., Huo, Y., Tang, S., Gökbağ, B., Fan, K., Huang, Y., Wang, L., Nagy, G., Parvin, J., Stover, D., Cheng, L., & Li, L. (2025). CRISPR-Cas9 Genome and Double-Knockout Screening to Identify Novel Therapeutic Targets for Chemoresistance in Triple-Negative Breast Cancer. Cancers, 17(23), 3876. https://doi.org/10.3390/cancers17233876